The US company CervoMed announced yesterday that the FDA has granted Orphan Drug Designation to its oral investigational ...
which already has an FDA green light for its Igalmi (dexmedetomidine) drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s ...
GlobalData on MSN7d
CervoMed’s stock rises as FDA grants orphan drug status to dementia drugThere are currently no available treatment options for any form of frontotemporal dementia that have been approved by the EMA ...
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...
Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...
Eli Lilly has backed away from plans to file Alzheimer's drug donanemab in the first ... in the hope of being allowed by the FDA to make the drug available to patients while its confirmatory ...
(RTTNews) - CervoMed, Inc. (CRVO) announced Wednesday that its oral investigational drug neflamapimod has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the ...
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback